About Cellsonics

Dr. Conley leads new investments for the firm while serving as an active Director on many of Paladin’s portfolio company Boards. Paul joined the Paladin team after more than 15 years of previous R&D and entrepreneurial experience. As founding CEO of BrightScale, he led the commercialization of a patented multi-core microprocessor technology in the HDTV market. As founding CEO of Appfluent Technology, he led the commercialization of patented in-memory distributed database technologies in the enterprise IT market. Prior to taking the entrepreneurial route, he spent nearly a decade in multidisciplinary R&D roles in the areas of high-performance computing, applied physics, and biomedical engineering, including postdoctoral positions at the Los Alamos National Laboratory. Paul earned a PhD in Computational Physics and an MS in Bioengineering from UCSD, as well as an MS and BS in Mechanical and Aerospace Engineering from the University of Virginia.

Formerly President of Tecan Systems, Steve has over 20 years experience leading the development, manufacturing, marketing and business development of sample preparation instrumentation for research and clinical applications ranging from molecular diagnostics, flow cytometry, HPLC to dried blood spot extraction.

Vibhu co-founded Microsonic Systems bringing the Hendrix SM100 Ultrasonic Fluid Processor from concept to market commercializing Bulk Lateral Ultrasonic energy.Vibhu has 20 years of full product life cycle experience with ultrasonic & MEMS, robotics, and medical devices.Vibhu has 7 issued patents and several provisional patents, and has been the principal investigator on multiple NIH and NASA funded government grants.

Dan is a Managing Director with OMX Ventures and has served on the Cellsonics board of directors since 2021. Dan brings over 18 years of experience in venture capital investing, life science strategy consulting, and biomedical research to the team, including deep expertise in early-stage company building and investing. Prior to co-founding OMX Ventures in 2020, Dan was a Principal on the venture capital team with Merieux Equity Partners. He also spent 5 years with L.E.K. Consulting in their life sciences strategy consulting team. Dan holds a PhD in Biomedical Sciences from U.C. San Diego, and a Bachelor’s degree in biology from Rhode Island College.

Dr. Marton serves as a consultant to industry and to nonprofit, government, and academic institutions. In the nonprofit sector, Dr. Marton is an Emeritus Member of the Board of Trustees of the American Association for Cancer Research Foundation and is on the Board of Directors of Cancer Commons. In the for-profit sector, he serves on the Boards of Directors of Cellsonics, Matternet, Microsonic Systems, Nanotics, Omniox (also serving as Executive Chair), RenovoRx, and xCures and is an advisor to Assurance Health Data, Enable Medicine, PharmaJet, and the Precision Medicine World Conference.Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. Dr. Marton received his MD from the Albert Einstein College of Medicine.

Parag Jhaveri has 20 years of industry and investing experience in venture capital, corporate strategy, M&A, and commercialization for Life Science, Tools & Diagnostics, and working with PE clients and early-stage venture-backed companies.Prior to his venture capital career, Parag led Corporate Strategy at Quantum-Si, a protein sequencing company and was an Associate Partner with Accenture’s Strategy & Consulting practice focused on strategy consulting and M&A. Before Accenture, he was with McKesson’s Specialty Health Business unit as a Director of Corporate Strategy and Business Development where he focused on operating model changes, strategic planning, and M&A. He also worked for KPMG’s Healthcare Deals Advisory practice focused on due diligence, strategy, and data analytics for corporate and PE companies. He has strong operational and commercialization experience from Life Technologies’ (acquired by ThermoFisher Scientific for $14B) Next Generation Sequencing business unit and Becton, Dickinson, and Company’s Cancer Diagnostics business unit. Parag holds an MBA from Haas School of Business, UC Berkeley, after receiving a MS in Industrial Engineering from Louisiana Tech University and BE in Mechanical Engineering from the University of Mumbai.